This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Clostridium botulinum

Authoring team

Clostridium botulinum is one species of the genus Clostridia. It is a Gram-positive, motile rod. Morphologically, it possesses sub-terminal spores. It only grows in an anaerobic environment where it produces irregular colonies on normal media.

Its natural habitat is the soil, but it can contaminate vegetables, fruit and other foods.

There are seven types of C. botulinum - A,B,C,D,E, F and G - each produces an antigenically different toxin.

  • seven different strains of Clostridium have been described (designated A, B, C (1 and 2), D, E, F and G), and each produces a distinct neurotoxin identified by the corresponding letter of the bacterial strain producing it, so, there are 7 distinct neurotoxins (BTX-A, -B, -C, -D, -E, -F, -G) (1)
    • humans can be affected by the toxins of 5 strains (A, B, E, F and G) and are not affected by the toxins of strains C and D
    • all 7 toxins may potentially cause botulism in humans given a high enough exposure (1)
    • alll 7 neurotoxins are structurally similar but immunologically distinct
      • there is some serum cross-reactivity among the serotypes because they share some sequence homology with one another as well as with tetanus toxin

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.